通过PDX模型与线粒体靶向推进儿童急性髓系白血病精准治疗
该研究建立26例儿童急性髓系白血病(pAML)患者来源异种移植(PDX)模型,覆盖14种高危遗传亚型,保留原发白血病的免疫表型、基因组和转录组特征。在KMT2A重排AML中,维奈克拉联合线粒体复合物I抑制剂IACS-010759可减少疾病进展,提示线粒体靶向治疗潜力。
要点
- pAML PDX模型可忠实重现原发白血病的分子复杂性与异质性。
- KMT2A重排AML中维奈克拉联合IACS-010759可减缓疾病进展。
- 联合基质靶向药物在耐药模型中亦减缓AML进展。
核心结论
- AML PDX可作为识别新型靶向治疗的可转化平台。
- 维奈克拉联合IACS-010759的临床前结果支持在KMT2A重排AML中靶向线粒体。
研究设计与样本
- 研究建立26例pAML患者来源异种移植(PDX)模型,代表14种高危遗传亚型。
- 对KMT2A重排AML中可成药变异和异常激活通路进行体外药物筛选,采用预测性三维共培养模型,并在AML PDX中进行体内验证。
主要发现
- PDX忠实重现原发AML的分子复杂性和异质性,并保留免疫表型、基因组和转录组特征。
- 从患者样本到匹配PDX可追踪克隆和转录组动态,并识别可作为治疗靶点的脆弱性。
- IACS-010759(线粒体复合物I抑制剂)联合维奈克拉(B细胞淋巴瘤2抑制剂)在模拟发病和复发的KMT2A重排PDX中减少AML进展。
- 维奈克拉联合IACS-010759及基质靶向药物在耐药模型中减缓AML进展。
临床怎么用
- PDX模型可用于pAML新型靶向治疗的临床前评估与筛选。
- KMT2A重排AML可考虑线粒体靶向联合BCL2抑制的临床前策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In pediatric acute myeloid leukemia (pAML) relapse/refractory (R/R) disease occurs frequently, but underlying mechanisms are unclear and effective second-line therapeutic options remain limited. Although genomic characterization has advanced targeted treatments, their clinical implementation, particularly in the pediatric field, is hindered by toxicities or resistance due to poor correlation between preclinical and clinical studies. The use of more robust preclinical models is crucial for developing effective therapies. We established 26 patient-derived xenografts (PDXs) of pAML representing 14 high-risk genetic subtypes. These PDXs faithfully recapitulated the molecular complexity and heterogeneity of primary AML, and preserved the immunophenotypic, genomic, and transcriptomic profiles. Clonal and transcriptomic dynamics were tracked from patient samples to their matched PDXs, and vulnerabilities that could be exploited as therapeutic targets were identified, facilitating the evaluation of multifaceted therapeutic strategies. We selected druggable variants and aberrantly activated pathways in KMT2A-rearranged (KMT2A-r) AML and performed an in vitro drug screening of actionable targets exploiting a predictive 3-dimensional coculture model. Promising compounds were tested in vivo in AML PDXs. Among new drugs targeting variants and pathways, we demonstrate that the combination of IACS-010759, a mitochondrial complex I inhibitor, and venetoclax, a B-cell lymphoma 2 inhibitor, reduces AML progression in KMT2A-r PDXs modeling both disease onset and relapse. The combination of venetoclax with IACS-010759 with a stromal targeting drug slowed AML progression in a resistant model. Overall, our study highlights the power of AML PDXs as a translational platform for novel targeted therapy identification. Our preclinical results testing venetoclax with IACS-010759 in KMT2A-r AML strongly support mitochondrial targeting in this genetic AML subtype.
引用
- Da Ros A, Peloso A, Longo G, et al. Advancing precision therapy in pediatric acute myeloid leukemia through PDX models and mitochondrial targeting. Blood Adv. 2026. PMID: 41576348. doi:10.1182/bloodadvances.2025018002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。